Literature DB >> 24267548

Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.

Caroline P Le1, Tara Karnezis, Marc G Achen, Steven A Stacker, Erica K Sloan.   

Abstract

The progression of cancer is supported by a wide variety of non-neoplastic cell types which make up the tumour stroma, including immune cells, endothelial cells, cancer-associated fibroblasts and nerve fibres. These host cells contribute molecular signals that enhance primary tumour growth and provide physical avenues for metastatic dissemination. This article provides an overview of the role of blood vessels, lymphatic vessels and nerve fibres in the tumour microenvironment and highlights the interconnected molecular signalling pathways that control their development and activation in cancer. Further, this article highlights the known pharmacological agents which target these pathways and discusses the potential therapeutic uses of drugs that target angiogenesis, lymphangiogenesis and stress-response pathways in the different stages of cancer care.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  NSAID; SNS; angiogenesis; beta-blocker; lymphangiogenesis; nerve fibres; sympathetic nervous system; vasculature

Mesh:

Substances:

Year:  2013        PMID: 24267548      PMCID: PMC4007214          DOI: 10.1016/j.bpa.2013.10.008

Source DB:  PubMed          Journal:  Best Pract Res Clin Anaesthesiol        ISSN: 1521-6896


  184 in total

1.  Cancer incidence and survival following bereavement.

Authors:  I Levav; R Kohn; J Iscovich; J H Abramson; W Y Tsai; D Vigdorovich
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

Review 2.  Lymphatic endothelium: an important interactive surface for malignant cells.

Authors:  Rae H Farnsworth; Marc G Achen; Steven A Stacker
Journal:  Pulm Pharmacol Ther       Date:  2005-04-25       Impact factor: 3.410

3.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.

Authors:  D A Kujubu; B S Fletcher; B C Varnum; R W Lim; H R Herschman
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

4.  VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme.

Authors:  W Debinski; B Slagle-Webb; M G Achen; S A Stacker; E Tulchinsky; G Y Gillespie; D M Gibo
Journal:  Mol Med       Date:  2001-09       Impact factor: 6.354

5.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Authors:  Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean-Marie Stassen; Mieke Dewerchin; Desire Collen; Peter Carmeliet
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

6.  Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas.

Authors:  R N DuBois
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

7.  Altered eicosanoid levels in human colon cancer.

Authors:  B Rigas; I S Goldman; L Levine
Journal:  J Lab Clin Med       Date:  1993-11

Review 8.  Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.

Authors:  Damien Gerald; Sudhakar Chintharlapalli; Hellmut G Augustin; Laura E Benjamin
Journal:  Cancer Res       Date:  2013-03-06       Impact factor: 12.701

9.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Authors:  P Salven; A Lymboussaki; P Heikkilä; H Jääskela-Saari; B Enholm; K Aase; G von Euler; U Eriksson; K Alitalo; H Joensuu
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

10.  Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis.

Authors:  Tanja Holopainen; Pipsa Saharinen; Gabriela D'Amico; Anita Lampinen; Lauri Eklund; Raija Sormunen; Andrey Anisimov; Georgia Zarkada; Marja Lohela; Hanna Heloterä; Tuomas Tammela; Laura E Benjamin; Seppo Ylä-Herttuala; Ching Ching Leow; Gou Young Koh; Kari Alitalo
Journal:  J Natl Cancer Inst       Date:  2012-02-17       Impact factor: 13.506

View more
  6 in total

Review 1.  Long-term Consequences of the Acute Neural-Inflammatory Stress Response in the Cancer Surgical Patient: New Findings and Perspectives.

Authors:  Bernhard Riedel; Erica Sloan; Patrice Forget
Journal:  Int Anesthesiol Clin       Date:  2016

Review 2.  Many Voices in a Choir: Tumor-Induced Neurogenesis and Neuronal Driven Alternative Splicing Sound Like Suspects in Tumor Growth and Dissemination.

Authors:  Zodwa Dlamini; Kgomotso Mathabe; Llewellyn Padayachy; Rahaba Marima; George Evangelou; Konstantinos N Syrigos; Arianna Bianchi; Georgios Lolas; Rodney Hull
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

Review 3.  Neural regulation of cancer: from mechanobiology to inflammation.

Authors:  Tae-Hyung Kim; Amy C Rowat; Erica K Sloan
Journal:  Clin Transl Immunology       Date:  2016-05-13

Review 4.  Drug repurposing in cancer neuroscience: From the viewpoint of the autophagy-mediated innervated niche.

Authors:  Jiayan Shi; Jia Xu; Yang Li; Bowen Li; Hui Ming; Edouard C Nice; Canhua Huang; Qifu Li; Chuang Wang
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

5.  β2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion.

Authors:  Sarah J Creed; Caroline P Le; Mona Hassan; Cindy K Pon; Sabine Albold; Keefe T Chan; Matthew E Berginski; Zhendong Huang; James E Bear; J Robert Lane; Michelle L Halls; Davide Ferrari; Cameron J Nowell; Erica K Sloan
Journal:  Breast Cancer Res       Date:  2015-11-25       Impact factor: 6.466

6.  Stress-driven lymphatic dissemination: An unanticipated consequence of communication between the sympathetic nervous system and lymphatic vasculature.

Authors:  Caroline P Le; Erica K Sloan
Journal:  Mol Cell Oncol       Date:  2016-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.